Uppsala Reports editor
@UMCGlobalSafety
The READUS-PV statement is the first-ever guide for reports of disproportionality analyses that are replicable, reliable, and reproducible.
Disproportionality analyses are a mainstay of pharmacovigilance research, but despite their prevalence are often misinterpreted, misunderstood, and sometimes misguided.
This is why Michele Fusaroli, Daniele Sartori, and their colleagues published the READUS-PV statement, the first-ever guide to reporting disproportionality analyses. Tune in to find out more about these guidelines and how they came to be, the history and overall impact of guidelines in pharmacological research, and what it means to publish "good" pharmacovigilance science.
Subscribe by visiting the Drug Safety Matters website.
Uppsala Reports editor
@UMCGlobalSafety
While underreporting remains a persistent global challenge, innovative approaches are showing promise in different regions
18 February 2026
Complementary medicines are widely used and often perceived as safe, yet high doses, product stacking, and unclear labelling can quietly increase the risk of harm.
07 April 2026
An Australian research team is using artificial intelligence to improve the safe dosing of unfractionated heparin, a high-risk drug linked to serious side effects.
30 March 2026